The Strategies for Treating “Alzheimer's Disease”: Insulin Signaling May Be a Feasible Target

G You, J Yao, Q Liu, N Li - Current issues in molecular biology, 2022 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by senile plaques
formed by amyloid-beta (Aβ) extracellularly and neurofibrillary tangles (NFTs) formed by …

The deficits of insulin signal in Alzheimer's disease and the mechanisms of vanadium compounds in curing AD

J Yao, Z He, G You, Q Liu, N Li - Current Issues in Molecular Biology, 2023 - mdpi.com
Vanadium is a well-known essential trace element, which usually exists in oxidation states in
the form of a vanadate cation intracellularly. The pharmacological study of vanadium began …

Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease

G García-Lluch, A Marseglia, LM Royo… - Journal of …, 2024 - journals.sagepub.com
Background It has been hypothesized that insulin resistance is pivotal in mediating amyloid
and tau dysregulations in Alzheimer's disease (AD). Objective To investigate the impact of …

Therapeutic Effects of Metformin on Central Nervous System Diseases: A Focus on Protection of Neurovascular Unit

C Cai, C Gu, C Meng, S He, L Thashi, D Deji… - Pharmaceutical …, 2024 - Springer
Metformin is one of the most commonly used oral hypoglycemic drugs in clinical practice,
with unique roles in neurodegeneration and vascular lesions. Neurodegeneration and …

Metformin attenuates white matter microstructural changes in Alzheimer's disease

S Abbaszadeh, G Raei Dehaghi… - Neurology …, 2024 - neurologyletters.com
Objectives: A body of evidence suggests that individuals with diabetes face an elevated
susceptibility to developing Alzheimer's disease when compared to the general populace …

Paraparésie secondaire à la metformine: une situation rare à connaître avec des images IRM caractéristiques

H Mourabiti, G Esayh, H Hoummani, SA Hanchi… - … Analytique et Clinique, 2024 - Elsevier
Résumé Cet article décrit le cas d'une patiente diabétique de type 2 ayant développé une
paraparésie spastique, une faiblesse des membres inférieurs, après cinq mois de traitement …